Monmouth Junction-based CytoSorbents Corp. was recently awarded a new preferred supplier agreement for CytoSorb with the Asklepios Group, one of the largest private hospital operators in Germany.
The three-year preferred supplier agreement will make CytoSorb available without restrictions to all of the approximate 170 health care facilities across 14 states throughout Germany that Asklepios operates. This includes Asklepios Klinik St. Georg in Hamburg, Germany, which pioneered the use of CytoSorb to remove antithrombotic drugs during cardiothoracic surgery and is well-known for its seminal publication on CytoSorb use for this application during emergency cardiac surgery in patients at high risk of bleeding.
“We are excited to announce this agreement with Asklepios, as we are now their preferred supplier of hemoadsorption technology,” Dr. Christian Steiner, executive vice president, sales and marketing, of CytoSorbents stated. “With this new agreement, CytoSorbents now has preferred supplier agreements with the three largest hospital chains in Germany, providing an opportunity to further grow our business. These privately-owned hospital chains are always seeking value-added therapies that provide both clinical and economic benefit to ensure the highest quality medical care for their patients while supporting profitable operations. I am convinced CytoSorb is helping these hospital chains achieve both objectives.”
